Vaccinia Immune Globulin Intravenous (Human) (Cnj-016)
Vaccinia Immune Globulin Intravenous (Human) is an FDA-licensed reference biologic from Emergent BioSolutions Canada Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2005
Reference approved
Reference product
Cnj-016 Vaccinia Immune Globulin Intravenous (Human)
Emergent BioSolutions Canada Inc.
- Approved
- May 02, 2005
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Vaccinia Immune Globulin Intravenous (Human), in chronological order.
Reference approval
Approval date of the reference Vaccinia Immune Globulin Intravenous (Human) product.
21 yr 5 mo ago
Frequently asked questions
Are there biosimilars approved for Vaccinia Immune Globulin Intravenous (Human) (Cnj-016)?
No 351(k) biosimilars or interchangeable biosimilars referencing Vaccinia Immune Globulin Intravenous (Human) are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.